Dr. Colón brings over 25 years of experience in biopharma, genomics, healthcare and industrial biotechnology. Most recently, she was CEO and President of InCarda Therapeutics from 2013 to 2022, where she led the company from a seed stage start-up to one with a best-in-class inhaled cardiovascular disease therapy being evaluated in a pivotal Phase 3 trial and a growing pipeline. She serves on the boards of CareDx (NASDAQ:CDNA), the MIT Corporation (MIT’s Board of Trustees) and the Biotechnology Innovation Organization (BIO), and is also Executive Chairman (formerly CEO) of ProterixBio. Formerly, she was a partner at New Science Ventures, a New York based venture capital firm with over $700M under management, and served on the boards of Paradigm Diagnostics, PerceptiMed and Cocoon Biotech and on the Advisory Board of the Miller Center for Social Entrepreneurship at Santa Clara University.
Previously, she was founding President of the Industrial Products Division at Intrexon Corporation, where she established a new division focused on leveraging synthetic biology for bioindustrial applications such as biofuels and renewable chemicals. She also co-founded Pyranose Biotherapeutics, a biologics discovery platform company. Before that she was head of Clinical Operations for Gilead Sciences, where she was responsible for global execution of clinical trials. She also created and led both the Alliance Management and Commercial Strategic Planning groups. Prior to Gilead, she was VP, Corporate Planning at Affymetrix, where she was responsible for strategic planning and project management and where she also served as COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics. Earlier in her career she was a consultant with McKinsey & Co., where she served clients in healthcare, biotech, high tech and venture capital. She was also an engineer with Merck & Co. in France and in Rahway, NJ.
Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was an NSF Fellow. She also holds a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.
Previously, she was founding President of the Industrial Products Division at Intrexon Corporation, where she established a new division focused on leveraging synthetic biology for bioindustrial applications such as biofuels and renewable chemicals. She also co-founded Pyranose Biotherapeutics, a biologics discovery platform company. Before that she was head of Clinical Operations for Gilead Sciences, where she was responsible for global execution of clinical trials. She also created and led both the Alliance Management and Commercial Strategic Planning groups. Prior to Gilead, she was VP, Corporate Planning at Affymetrix, where she was responsible for strategic planning and project management and where she also served as COO for the International Genomics Consortium, a non-profit medical research organization focused on cancer genomics. Earlier in her career she was a consultant with McKinsey & Co., where she served clients in healthcare, biotech, high tech and venture capital. She was also an engineer with Merck & Co. in France and in Rahway, NJ.
Dr. Colón received her Ph.D. in chemical engineering from the Massachusetts Institute of Technology, where she was an NSF Fellow. She also holds a B.S. degree in chemical engineering from the University of Pennsylvania, where she was a Benjamin Franklin Scholar.
Speaking In
10:00 AM - 10:45 AM (EST)
Monday, February 6
Strategies for Raising Venture Capital or Securing Additional Financing: Tips for Biotech Executives
With the volatility of public markets in 2022, many companies have considered additional raises…
South Broadway Ballroom